k 2022

Self-emulsifying System Incorporated in a Polymeric Carrier for Controlled Delivery of Thymol

KOUTNÁ, Gabriela, Miroslava PAVELKOVÁ, Kateřina KUBOVÁ, Martina ČUBOVÁ URBANOVÁ, Jiří BRUS et. al.

Basic information

Original name

Self-emulsifying System Incorporated in a Polymeric Carrier for Controlled Delivery of Thymol

Authors

KOUTNÁ, Gabriela (203 Czech Republic, belonging to the institution), Miroslava PAVELKOVÁ (203 Czech Republic, guarantor, belonging to the institution), Kateřina KUBOVÁ (203 Czech Republic, belonging to the institution), Martina ČUBOVÁ URBANOVÁ (203 Czech Republic), Jiří BRUS (203 Czech Republic), Jan MUSELÍK (203 Czech Republic, belonging to the institution), Jakub VYSLOUŽIL (203 Czech Republic, belonging to the institution) and David VETCHÝ (203 Czech Republic, belonging to the institution)

Edition

NanoMed 2022, 2022

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14160/22:00127158

Organization unit

Faculty of Pharmacy

Keywords (in Czech)

pektin; alginát; hydrogelové částice; samoemulgující systém; thymol; řízené uvolňování léčiva; nespecifické střevní záněty

Keywords in English

pectin; alginate; hydrogel particles; self emulsifying system; thymol; controlled release of drug; nonspecific intestinal inflammations

Tags

Tags

International impact
Změněno: 2/12/2022 13:39, JUDr. Sabina Krejčiříková

Abstract

V originále

The biocompatibility and biodegradability of natural polymers make them an object of interest for many applications in biomedicine and pharmacy. Their ability to control drug release makes them very significant pharma-ceutical excipients for formulating dosage forms, especially particulate dosage forms. These advantages, together with encapsula-tion of natural active agents and the use of some soft method for their preparation, an "eco-friendly" drug dosage form could pro-vide. Many natural active ingredients today are experiencing a comeback. However, most of them have low solubility, leading to low bioavailability and ultimately low therapeutic efficacy. Therefore, a way of their modifica-tion and incorporation into the dosage form plays a crucial role in their therapeutic effec-tiveness. There are many methods to increase the bio-availability of poorly soluble drugs after oral administration. The formation of a self-emulsifying system (SES) ensures the dis-solving of lipophilic active substance and, after its reconstitution, the shape of o/w emulsion, which is necessary for drug ab-sorption either in the systemic circulation or inflamed mucosa. This systemic or local ef-fect depends on the drop size of the internal phase of the emulsion, whether the nanoemulsion, microemulsion, or macro-emulsion is created (1). Thus, this paper discusses a dosage form of pectin/alginate particles as a carrier of SES with dissolved monoterpene thymol. It is a drug with a wide range of biological effects (antimicrobial, antiviral, antifungal, anti-inflammatory, antioxidant, antineoplastic, etc.) with potential usage in nonspecific intes-tinal inflammations (NSZ). Nowadays, the treatment of NSZ includes mostly cortico-steroids and antibiotics administration, so that this new approach could become an alterna-tive to this treatment. Thymol's incorporation into the SES containing triacylglycerols, Labrasol®, and propylene glycol in ratio 2:7:1 and their subsequent solidification in pec-tin/alginate particles lead to the final solid drug form formation. The evaluation of the morphological parameters using optical and electron microscopes, evaluation of swelling capacity and dissolution profiles, and finally, the assessment of the formed emulsion after SES reconstitution in a phosphate buffer pH 6 are integral parts of this experiment.

Links

GA22-03187S, research and development project
Name: Racionální design částicových polysacharidových systémů pro přívod léčiv s širokým spekterem biologické aktivity k terapii sliznic (Acronym: 22-03187S)
Investor: Czech Science Foundation